A 58-year-old male smoker presents with a 3-month history of cough, chest pain, and weight loss. Imaging reveals a central lung mass with mediastinal lymphadenopathy. Bronchoscopic biopsy confirms small cell lung cancer (SCLC) with extensive stage disease. Which is the drug of choice for first-line chemotherapy in this patient?

Explanation

## First-Line Chemotherapy for Small Cell Lung Cancer **Key Point:** Cisplatin + Etoposide (PE) is the gold-standard first-line regimen for both limited-stage and extensive-stage SCLC, established by decades of clinical trials and endorsed by all major guidelines. ### Mechanism of Action - **Cisplatin:** Platinum-based alkylating agent; forms DNA cross-links → apoptosis - **Etoposide:** Topoisomerase II inhibitor; prevents DNA unwinding → strand breaks ### Why PE is Superior in SCLC | Feature | Cisplatin + Etoposide | Carboplatin + Pemetrexed | Docetaxel + Cisplatin | |---------|----------------------|--------------------------|------------------------| | **SCLC efficacy** | Gold standard (ORR 60–80%) | Non-SCLC agent (adenocarcinoma) | Inferior in SCLC | | **Toxicity profile** | Manageable with hydration | Myelosuppression, renal | Peripheral neuropathy | | **Evidence base** | Level 1A (multiple RCTs) | Level 3 (NSCLC trials) | Level 3 (NSCLC trials) | | **Guideline recommendation** | NCCN, ESMO, ASCO | Not recommended for SCLC | Not recommended for SCLC | **High-Yield:** SCLC is exquisitely chemosensitive — PE achieves response rates of 60–80% in extensive-stage disease, but median overall survival remains 10–12 months without maintenance therapy or immunotherapy. ### Dosing Schedule - Cisplatin 75 mg/m² IV day 1 + Etoposide 100 mg/m² IV days 1–3 - Repeated every 3 weeks for 4–6 cycles - Hydration and antiemetics mandatory **Clinical Pearl:** Carboplatin may substitute for cisplatin in patients with renal impairment or hearing loss, but pemetrexed is a non-small-cell agent and is not indicated for SCLC. **Warning:** Pemetrexed is specifically designed for non-squamous NSCLC and adenocarcinoma; using it in SCLC represents a fundamental misunderstanding of lung cancer histology-directed therapy. ### Modern Additions (Post-First-Line) - Atezolizumab (PD-L1 inhibitor) added to PE in extensive-stage SCLC improves OS (IMpower133 trial) - However, the chemotherapy backbone remains PE [cite:Harrison 21e Ch 105]